Literature DB >> 11166888

Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.

Y Hagiwara1, T Iwasaki, H Asanuma, Y Sato, T Sata, C Aizawa, T Kurata, S Tamura.   

Abstract

Effects of intranasal administration of cholera toxin (CT) [or Escherichia coli heat-labile enterotoxin (LT)] B subunits supplemented with a trace amount of the holotoxin, CTB* or LTB*, on the brain were examined in BALB/c mice by comparing with those of the intracerebral injection. Intracerebral injection of CTB* at doses more than 10 microg/mouse caused significant body weight loss and dose-dependent death within 7 days, with localization of conjugates of horseradish peroxidase with CTB (HRP-CTB) in the ventricular system and in the perineural space of olfactory nerves of the nasal mucosa 3 h after injection. Intracerebral injection of CTB* at doses less than 3 microg/mouse (or LTB* at doses less than 22.7 microg/mouse) did not cause any significant body weight loss for 7 days, with localization of HRP-CTB in the brain but not in the nasal mucosa. On the other hand, intranasal administration of 10 microg of CTB* caused localization of HRP-CTB in the nasal mucosa but not in the brain 3 h after administration and caused body weight loss even after 30 administrations. Neither any histological changes of brain tissues nor marked changes in serum biochemical parameters were found in mice after the 30 administrations of CTB* or LTB*. These results suggest that 0.1 microg of CTB* or LTB*, which is known to be close to the minimal effective dose as an adjuvant for nasal influenza vaccine in mice and corresponds to 100 microg per person, can be used as a safe nasal adjuvant without adversely affecting the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166888     DOI: 10.1016/s0264-410x(00)00412-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

2.  Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.

Authors:  Tetsuya Harakuni; Hideki Sugawa; Ai Komesu; Masayuki Tadano; Takeshi Arakawa
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.

Authors:  Britni M Arlian; Juliette K Tinker
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

4.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Nasal immunization with a fusion protein consisting of the hemagglutinin A antigenic region and the maltose-binding protein elicits CD11c(+) CD8(+) dendritic cells for induced long-term protective immunity.

Authors:  Yuan Du; Tomomi Hashizume; Tomoko Kurita-Ochiai; Satoshi Yuzawa; Yoshimitsu Abiko; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

6.  A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Authors:  Yukari Hagiwara; Yuki I Kawamura; Kosuke Kataoka; Bibi Rahima; Raymond J Jackson; Katsuhiro Komase; Taeko Dohi; Prosper N Boyaka; Yoshifumi Takeda; Hiroshi Kiyono; Jerry R McGhee; Kohtaro Fujihashi
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

7.  Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Authors:  Takeshi Ichinohe; Izumi Watanabe; Satoshi Ito; Hideki Fujii; Masami Moriyama; Shin-Ichi Tamura; Hidehiro Takahashi; Hirofumi Sawa; Joe Chiba; Takeshi Kurata; Tetsutaro Sata; Hideki Hasegawa
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.

Authors:  Takeshi Arakawa; Ai Komesu; Hitoshi Otsuki; Jetsumon Sattabongkot; Rachanee Udomsangpetch; Yasunobu Matsumoto; Naotoshi Tsuji; Yimin Wu; Motomi Torii; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

9.  Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies.

Authors:  Fumiki Momoi; Tomomi Hashizume; Tomoko Kurita-Ochiai; Yoshikazu Yuki; Hiroshi Kiyono; Masafumi Yamamoto
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

10.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.